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Abstract
Thymulin is a thymic hormone exclusively produced by the thymic epithelial cells. It consists of a
nonapeptide component coupled to the ion zinc, which confers biological activity to the molecule.
After its discovery in the early 1970s, thymulin was characterized as a thymic hormone involved in
several aspects of intrathymic and extrathymic T cell differentiation. Subsequently, it was
demonstrated that thymulin production and secretion is strongly influenced by the neuroendocrine
system. Conversely, a growing core of information, to be reviewed here, points to thymulin as a
hypophysotropic peptide. In recent years, interest has arisen in the potential use of thymulin as a
therapeutic agent. Thymulin was shown to possess anti-inflammatory and analgesic properties in the
brain. Furthermore, an adenoviral vector harboring a synthetic gene for thymulin, stereotaxically
injected in the rat brain, achieved a much longer expression than the adenovirally mediated expression
in the brain of other genes, thus suggesting that an anti-inflammatory activity of thymulin prevents
the immune system from destroying virus-transduced brain cells. Other studies suggest that thymulin
gene therapy may also be a suitable therapeutic strategy to prevent some of the endocrine and
metabolic alterations that typically appear in thymus-deficient animal models. The present article
briefly reviews the literature on the physiology, molecular biology, and therapeutic potential of
thymulin.
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Relevance of the Thymus in the Immune–Neuroendocrine Homeostatic
Network
The immune system is functionally linked to the nervous and endocrine systems thus
constituting an integrated homeostatic network.1 Within this network, the neuroendocrine
system monitors and controls the physical and chemical variables of the internal milieu. On its
part, the immune system perceives, through antigenic recognition, an internal image of the
macromolecular and cellular components of the body and reacts to alterations of this image,
effectively participating in the “biological” homeostasis of the organism.
In mammals, the interaction of the thymus gland with the neuroendocrine system seems to be
particularly important during perinatal life when the thymus and the neuroen-docrine system
influence the maturation of each other. This was initially suggested by early findings showing
that in species in which neonatal thymectomy does not produce any evident impairment of
immune capacity,2 neuroendocrine functions are already highly developed at birth.3 In mice,
the importance of the thymus for proper maturation of the neuroendocrine system is revealed
by the endocrine alterations caused by neonatal thymectomy or congenital absence of the
thymus. In effect, congenitally athymic (nude) female mice show significantly reduced levels
of circulating and pituitary gonadotropins, a fact that seems to be causally related to a number
of reproductive derangements described in these mutants.4 Thus, in homozygous (nu/nu)
females the times of vaginal opening and first ovulation are delayed,5 fertility is reduced,4 and
follicular atresia is increased such that premature ovarian failure results.6 Similar abnormalities
result from neonatal thymectomy of normal female mice.7,8 Ovaries of athymic mice respond
normally to exogenous gonadotropins, suggesting that the defect is at the level of the
hypothalamic–pituitary axis.9,10 In homozygous, adult, nude CD-1, male mice, thyrotropin
(TSH), prolactin (PRL), growth hormone (GH), and gonadotropin responses to immobilization
and cold stress are reduced as also are serum basal levels of the same hormones compared to
the heterozygous counterparts.11–13 A functional impairment of the hypothalamic–adrenal
axis has been reported in nude mice, suggesting that humoral thymic factors may play a role
in the maturation of this axis.14
The influence of the neuroendocrine system on thymus (and immune) function seems to
continue during adult life either through a direct action of pituitary hormones or via peripheral
hormones, both of which act on the thymic epithelial cells (TEC) and/or on immature
thymocytes within the gland (for a review, see Ref. 15).
Thymulin
Thymulin is a thymic metallopeptide involved in several aspects of intrathymic and
extrathymic T cell differentiation.16 Thymulin, which is exclusively produced by the thymic
epithelial cells,17 consists of a biologically inactive nonapeptide component termed FTS (an
acronym for serum thymus factor in French) coupled in an equimolecular ratio to the ion zinc,
18 which confers biological activity to the molecule.19 The metallopeptide active form bears
a specific molecular conformation that has been evidenced by nuclear magnetic resonance.20
Neuroendocrine Control of Thymulin Production
The control of thymulin secretion seems to be dependent on a complex network of events.
Initial studies showed that the hormone itself exerts a controlling feedback effect on its own
secretion both in vivo and in vitro.21,22 Additionally, thymulin production and secretion is
influenced directly or indirectly by the neuroendocrine system. For instance, GH can influence
thymulin synthesis and secretion. In vitro, human GH can stimulate thymulin release from TEC
lines,23 which are known to possess specific receptors for GH.24 Animal studies have shown
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that treatment of aged dogs with bovine GH partially restored their low thymulin serum levels.
25 In old mice, treatment with ovine GH increased their low circulating thymulin levels and
enhanced the concanavalin A-dependent proliferative response of their thymocytes as well as
interleukin-6 production.26 In old rats, combined treatment with GH and thyroxine (T4) was
also able to partially restore their reduced thymulin levels.27 In clinical studies, it was reported
that in congenitally GH-deficient children who consistently exhibited low plasma thymulin
levels GH therapy succeeded in increasing thymic hormone levels to near normal values.28
Acromegalic middleaged patients have elevated thymulin serum levels compared to age-
matched normal subjects.23,28 It is likely that these effects of GH are mediated, at least in
part, by insulin-like growth factor 1 (IGF-1) as suggested by the fact that the GH-induced
enhancement of thymulin production could be prevented by previous treatment with antibodies
against IGF-1 or IGF-1 receptor.23
There is also evidence for a PRL–thymulin axis. Thus, it is known that TEC possess PRL
receptors29 and that PRL can stimulate thymulin synthesis and secretion both in vitro and in
vivo.30 Furthermore, administration of PRL to old mice elevated their reduced circulating
levels of thymulin.30
The thyroid axis also influences thymulin secretion. Thus, T4 has been shown to stimulate
thymulin synthesis and secretion in mice.31 In vivo treatment of mice with triiodothyronine
enhanced thymulin secretion, whereas treatment of the animals with propylthiouracil, an
inhibitor of thyroid hormone synthesis, decreased their circulating thymulin levels.32 In
humans, hyperthyroidism brings about an increase in circulating thymulin levels, whereas
hypothyroid patients show depressed levels of this thymic hormone.33 In in vitro studies, it
was shown that thyroid hormones stimulate thymulin secretion by a direct action on TEC.34,
35 Interestingly, it has been shown that treatment of aged animals with T4 can reverse their
decreased thymulin levels.31,35
Although there are no studies documenting a direct effect of gonadotropins or
adrenocorticotropic hormone (ACTH) on thymulin secretion gonadectomy or adrenalectomy
in mice is known to induce a transient decrease in serum thymulin levels. This effect is
potentiated by the simultaneous removal of the adrenals and gonads.34 In TEC cultures it was
shown that exposure to physiological levels of glucocorticoids or gonadal steroids enhanced
thymulin concentration in the cell supernatants.36,37
Although there is no rigorous evidence proving the existence of hypothalamic factors able to
influence thymulin production by a direct action on TEC, there are two studies that suggest
that this may be the case. Treatment of old mice with hypothalamic extracts from young mice
resulted in the reappearance of detectable levels of circulating thymulin.38 Hypothalamic and
pituitary extracts from young mice stimulated thymulin release from TEC cultures, but this
stimulation declined when the pituitary and hypothalamic extracts were obtained from old
mice.39
Hypophysiotropic Activity of Thymulin
The multilateral influence that the neuroendocrine system exerts on thymulin secretion
suggests that this metallopeptide could, in turn, be part of a feedback loop acting on
neuroendocrine structures. This possibility is now supported by a significant body of evidence
indicating that thymulin possesses hypophysiotropic activity. Thus, thymulin has been shown
to stimulate luteinizing hormone (LH) release fromperifused rat pituitaries40 and ACTH from
incubated rat pituitary fragments, the latter being an effect mediated by intracellular cAMP
and cGMP accumulation.41 In an in vitro study using pituitary cells obtained from female rats
in different days of the estrous cycle, it was observed that thymulin modulates the stimulatory
activity of gonadotropin-releasing hormone on LH and follicle-stimulating hormone (FSH)
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release.42 Thymulin has been found to stimulate GH, PRL, TSH, and gonadotropin release in
dispersed rat pituitary cells at doses from 10−8 to 10−3 mol/L,43–45 whereas others have
reported that thymulin doses of 10−11 mol/L stimulate LH, inhibit PRL release, and have no
effect on GH secretion in incubated rat pituitary fragments.40 The stimulatory effect of
thymulin on hormone release in rat pituitary cells declines with the age of the cell donor, which
suggests that aging brings about a desensitization of the pituitary gland to thymic signals.43–
45
There is in vitro and in vivo evidence suggesting that thymulin plays a role in the regulation of
female spontaneous puberty, possibly through effects on pituitary gonadotropin release and
ovarian steroidogenesis.40,42,44–47 Thymulin also modulates gonadotropin-induced
testicular steroidogenesis.48
Recent immunoneutralization studies have strengthened the hypothesis that thymulin is a
physiological mediator of the perinatal influence of the thymus on neuroendocrine maturation.
Thus, neonatal immunoneutralization of circulating thymulin in otherwise normal C57BL/6
mice induced significant morphologic alterations in most anterior pituitary endocrine cell
populations when the animals reached puberty.49 Thymulin immunoneutralization from birth
to puberty in normal mice also induced serum gonadotropin50 and serum TSH, PRL, and GH
reduction (Goya et al., unpublished results) when the animals reached puberty.
Construction of Synthetic Genes for Thymulin
The prospect of implementing thymic hormone gene therapy appears as an interesting avenue
of research aimed at restoring endocrine thymic activitywhen thymus function is compromised.
However, none of the genes coding for the known thymic peptides have been cloned, a situation
that hinders the implementation of gene or other molecular therapies for thymic hormones. It
was suggested that a possible way to overcome this problem could be to construct “artificial
genes” coding for those thymic peptides whose amino acid sequences were short and required
no posttranslational processing.51 This has been recently achieved for thymulin and the
corresponding DNA sequence cloned in a recombinant adenoviral (RAd) vector that was
subsequently used in a number of experimental gene therapy studies (see below).
In an early study aimed at upscaling thymulin production, a synthetic DNA sequence coding
for FTS was inserted into a bacterial expression vector and successfully used to obtain large
quantities of purified thymulin retaining full biological activity.52 More recently, a DNA
sequence coding for the biologically active FTS analogue called metFTS was constructed and
cloned in an adenoviral vector.53 The design of the DNA sequence for metFTS was optimized
for expression in rat systems by choosing, for each amino acid of the native peptide, the codon
more frequently used by rat cells (Fig. 1A). A variant of this sequence was used to construct
RAd-metFTS, an adenoviral vector that harbors the synthetic gene for metFTS driven by the
mouse cytomegalovirus promoter (PmCMV) (Fig. 1B and C). When intramuscularly (i.m.)
administered to thymectomized (Tx) mice and rats (whose circulating levels of thymulin are
nondetectable), RAd-metFTS induced sustained supraphysiological serum levels of
biologically active thymulin that remained high for at least 112 days in mice53 and for over
320 days in rats. Interestingly, adenovirally mediated expression of the synthetic gene for
metFTS in the substantia nigra and hypothalamus of adult Tx rats had a significantly longer
duration than adenovirally mediated expression of the gene for green fluorescent protein or
Escherichia coli β-galactosidase in the same brain regions.54 This phenomenon could be a
result of the anti-inflammatory activity in the brain reported for thymulin and some thymulin
analogues.55,56 Additionally, results from experiments using intracere-broventricular
injection of thymulin in rats with experimentally induced brain inflammation suggested that
this peptide has a neuroprotective role in the central nervous system and indicate a possible
Reggiani et al. Page 4













therapeutic use as analgesic and anti-inflammatory drug.57 The anti-inflammatory activity
could prevent the immune system of the vector-injected animals from mounting a destructive
response against the transduced cells. The same rationale could explain the long-term
persistence of high concentrations of transgenic metFTS in the circulation of RAd-metFTS-
injected Tx rodents.53 Because thymulin has no known toxic effects even at high doses, i.m.
injection of RAd-metFTS could generate sustained pharmacologically effective levels of serum
and brain thymulin for the amelioration of pathologies involving chronic brain inflammation.
This would represent a distinct advantage over alternative anti-inflammatory approaches that
use direct brain injection of viral vectors that block the production or actions of pro-
inflammatory cytokines.58
Gene Therapy for Thymulin
Neonatal Thymulin Gene Therapy Prevents the Disruptive Impact of Athymia on the
Reproductive System of Female Mice
A single i.m. injection of RAd-metFTS in newborn nude mice (nude mice have undetectable
circulating levels of thymulin) elicited long-term restoration of serum thymulin in these
mutants. This treatment was able to prevent the deficits in serum LH and FSH that typically
appear in adult female nude mice.50 Furthermore, neonatal thymulin gene therapy in nude
female mice has been found to significantly prevent the ovarian dysgenesis that usually
develops in 70-day-old, female, nude mice.59
Effect of Neonatal Thymulin Gene Therapy on the Metabolic Dyshomeostasis in Nude Mice
There is evidence that the endocrine thymus may participate in glucose homeostasis. Thus, it
has been reported that after 1 month of age, nude BALB/c mice develop spontaneous
hyperglycemia and impaired glucose tolerance.60,61 Furthermore, these animals show
peripheral insulin insensitivity with normal pancreatic β-cell reserves and normal lean body
mass.62 Assessment of pancreatic islet cell populations in hyperglycemic nude mice revealed
an increase in the D cell population (somatostatin producing). Also, somatostatin content in
pancreatic tissue was higher in the athymic nude mice compared to heterozygous sex- and age-
matched counterparts.63 Adult thymectomy in Wistar rats was reported to increase circulating
insulin levels without significant changes in blood glucose.64 Other studies point to a
modulatory activity of thymic factors on lipid metabolism. Thus, a thymic protein factor was
reported to reduce serum cholesterol levels in rodents, increase low-density lipoprotein
catabolism, and inhibit the activity of hepatic 3-hydroxy-3-methylglutaryl (HMG)-CoA
reductase, the rate-limiting enzyme in cholesterol synthesis.65–67 In adult nude mice it has
been reported that the relative percentage of 16:0, 18:1 n9, and 18:1 n7 fatty acids is lower
whereas that of 18:0, 20:4 n6, and 22:6 n3 fatty acids is higher in hepatic phospholipids of nu/
nu animals compared to nu/+ counterparts. Some of these alterations were completely or
partially prevented by neonatal thymulin gene therapy.68 Neonatal thymulin gene therapy
completely prevented the adult-onset hyperglycemia of 70-day-old nude mice (Garcia-Bravo
et al., unpublished results).
Concluding Remarks
Thymulin is probably the best characterized of all putative thymic hormones and seems to play
a physiological role in thymus–pituitary communication, particularly during perinatal life.
Interest in the therapeutic use of thymulin flourished during the 1970s and 1980s when efforts
were almost exclusively focused on using thymulin (and other thymic peptides) for the
treatment of autoimmune and other immunopathologies as well as cancer.69,70 Subsequent
studies, most of them carried out during the last 15 years, established that thymulin is active
on the hypophysis and the brain. This awareness and the recent availability of a synthetic gene
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for metFTS have opened new avenues for the exploration and eventual exploitation of the
therapeutic potential of this metallopeptide.
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DNA constructs encoding the biologically active serum thymus factor (FTS) analogue
(metFTS) and assembly of an adenoviral vector (RAd-metFTS) that harbors the synthetic gene
for metFTS. A DNA sequence coding for native FTS was designed for optimal expression in
rat cells. By adding an ATG starting codon upstream and two stop codons downstream of this
sequence, it was converted into an open reading frame (ORF) for the analogue metFTS (A).
This metFTS ORF was used to generate a construct to be cloned in the shuttle vector pDC515.
The construct included the phage T7 promoter primer-binding site, which was used for
sequencing purposes (B). The shuttle pDC515-metFTS was generated by inserting the T7-
metFTS sequence into the BamHI and SalI sites of the multiple cloning site of the shuttle
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pDC515. This construct was used to generate RAd-metFTS (C). PmCMV, mouse
cytomegalovirus promoter; frt, recognition element for the yeast FLP recombinase; ITR,
inverted terminal repeats; ΔE1 and ΔE3, deletions in the Ad5 genome; SV40, simian virus 40
polyadenylation signal;ψ, packaging signal. From Ref. 50, used with permission.
Reggiani et al. Page 11
Ann N Y Acad Sci. Author manuscript; available in PMC 2010 February 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
